Pre-eclampsia (PE) is still a leading cause of maternal and perinatal mortality and morbidity in Ireland. PE is defined as recent onset hypertension (arterial pressure ≥ 140/90 mmHg).
Assays of pre-eclampsia biomarkers can be used for:
Screening Assay (1st trimester of pregnancy):
PIGF (Placental Growth Factor) is, together with PAPP-A, a biochemical marker for pre-eclampsia. Assays are performed during the first trimester of pregnancy. It is possible to calculate the risk of early-onset (before 34 weeks of gestation) or late-onset pre-eclampsia (before 37 SA). This calculation of risk includes data about the patient (BMI, smoker/non-smoker, geographic origin, etc.) the history (number of viable pregnancies, history of pre-eclampsia, hypertension) and pregnancy underway (dating: date of ultrasound and craniocaudal length) in addition to blood pressure and Doppler of uterine arteries.
Predictive Assay (>20 weeks of amenorrhea):
The predictive test is for patients between 20 and 37 weeks of gestation, at risk of pre-eclampsia with at least one warning sign. A low sFlt-1/PlGF ratio (<38) enables predicting the absence of pre-eclampsia (and complications) at 1 week (NPV 99.3%).